|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
30.55 USD |
-0.91% | -0.39% | -29.32% | |
Published on 05/16/2025 at 16:17
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Scholar Rock Holding Corporation, Q1 2025 Earnings Call, May 14, 2025 |
May. 14 |
|
|
Sector Update: Health Care Stocks Rise Premarket Wednesday |
May. 14 |
MT |
|
Scholar Rock Q1 Income From Operations USD -77.09 Million |
May. 14 |
RE |
|
Scholar Rock’s Q1 Net Loss Widens |
May. 14 |
MT |
|
Earnings Flash (SRRK) Scholar Rock Posts Q1 Net Loss $0.67 a Share, vs. FactSet Est of $0.66 Loss |
May. 14 |
MT |
|
Scholar Rock Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 14 |
CI |
|
Scholar Rock To Host Conference Call To Discuss First Quarter 2025 Financial Results And Provide Business Update On May 14, 2025 |
May. 07 |
RE |
|
Scholar Rock Holding Corporation – Special Call |
Apr. 28 |
|
|
Scholar Rock Names Chairman David Hallal as CEO |
Apr. 28 |
MT |
|
Scholar Rock Appoints David Hallal As CEO, Announces Addition Of Three Key Leaders |
Apr. 28 |
RE |
|
Scholar Rock Announces Executive Changes |
Apr. 28 |
CI |
|
Scholar Rock Appoints Vikas Sinha as Chief Financial Officer |
Apr. 28 |
CI |
|
Scholar Rock Announces CEO Changes |
Apr. 28 |
CI |
|
Scholar Rock Application for Spinal Muscular Atrophy Treatment Gets FDA Approval |
Mar. 25 |
DJ |
|
Scholar Rock Gets US FDA Priority Review for Potential Spinal Muscular Atrophy Treatment |
Mar. 25 |
MT |
|
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy |
Mar. 25 |
RE |
|
FDA Grants Priority Review for Biologics License Application and Ema Accepts Marketing Authorisation Application for Apitegromab as A Treatment for Spinal Muscular Atrophy |
Mar. 25 |
CI |
|
Scholar Rock appoints Erin Moore as interim Principal Financial Officer |
Mar. 21 |
RE |
|
Scholar Rock Holding Corporation Announces Executive Changes |
Mar. 21 |
CI |
|
Scholar Rock Holding Corporation Announces Executive Changes |
Mar. 21 |
CI |
|
Scholar Rock Study of Potential Spinal Muscular Atrophy Treatment Meets Secondary Endpoints |
Mar. 17 |
MT |
|
Scholar Rock Holding Insider Sold Shares Worth $5,068,974, According to a Recent SEC Filing |
Mar. 13 |
MT |
|
Wedbush Adjusts Scholar Rock Price Target to $50 From $47, Maintains Outperform Rating |
Feb. 27 |
MT |
|
Scholar Rock’s 2024 Loss Widens |
Feb. 27 |
MT |
SRRK: Dynamic Chart
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company to develop a proprietary platform for the development of monoclonal antibodies that locally and selectively target the precursor. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as the first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA). Its other product candidate, SRK-181, a selective inhibitor of the activation of latent TGFb, is being developed for the treatment of cancers.
More about the company
Buy
Average target price
50.50USD
Spread / Average Target
+63.80%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
